The malaria drug loses an EUA for COVID-19, while the FDA warns of drug interactions that can reduce antiviral effectiveness.
The malaria drug loses an EUA for COVID-19, while the FDA warns of drug interactions that can reduce antiviral effectiveness.
New developments with diagnostic testing and the use of chloroquine and hydroxychloroquine.
